Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001735276-23-000029
Filing Date
2023-03-01
Accepted
2023-03-01 16:22:35
Documents
2
Period of Report
2023-02-27

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT edgardoc.html 4  
1 PRIMARY DOCUMENT edgardoc.xml 4 7231
2 EDGAR SUPPORTING DOCUMENT garg_20230221poa.txt EX-24 4096
  Complete submission text file 0001735276-23-000029.txt   12857
Mailing Address 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE MA 02142
Business Address 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE MA 02142 (617) 551-8200
ALNYLAM PHARMACEUTICALS, INC. (Issuer) CIK: 0001178670 (see all company filings)

EIN.: 770602661 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O SQZ BIOTECHNOLOGIES COMPANY 200 ARSENAL YARDS BOULEVARD, SUITE 210 WATERTOWN MA 02472
Business Address
Garg Pushkal (Reporting) CIK: 0001829252 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36407 | Film No.: 23693928